glp 1 side effects eyesight GLP-1 medications and eye problem risks GLP 1 Blindness Risk |

March 2024 : The US FDA approved a label expansion for WEGOVY based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke in adults with either overweight or obesity and established CVD

& Oren, M

Support better overall metabolic function

GLP-1 drugs help brain insulin work normally again

Daily use is positioned as simple: one serving provides targeted probiotics plus a prebiotic fiber to help those strains thrive

And swirled in with all of this is the misplaced shame and embarrassment of needing to be on Ozempic in the first place, of having lost control to the point of needing medical intervention